Recent News

• 09.03.2025 - Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules
• 08.12.2025 - Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
• 07.31.2025 - Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split
• 07.24.2025 - Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Recent Filings

• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.04.2025 - DEF 14A Other definitive proxy statements
• 07.31.2025 - EX-99.1 EX-99.1
• 07.31.2025 - 8-K Current report
• 07.24.2025 - PRE 14A Other preliminary proxy statements
• 07.23.2025 - EFFECT Notice of Effectiveness
• 07.21.2025 - CORRESP Correspondence
• 07.21.2025 - UPLOAD SEC-generated letter